Tirzepatide
SURMOUNT-CN
Eli Lilly · Phase 3 · Completed · Enrollment 210
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| 10 Milligrams (mg) Tirzepatide | Obesity or overweight | n/r | n/r | n/r | n/r |
| 15 mg Tirzepatide | Obesity or overweight | 15 mg | 52 | n/r | n/r |
| Placebo | Obesity or overweight | n/r | 52 | n/r | n/r |
| 10 mg Tirzepatide | Obesity or overweight | 10 mg | 52 | n/r | n/r |